glp-1 approved for type 1 diabetes Why Agonists May Not Be Safe People with In type 1 patients with

A fermentation process takes place as your gut bacteria digests carbohydrates

Increased adverse metabolic effects (diabetes, weight gain, dyslipidemia, and increased cardiovascular risk) are common during neuropsychiatric drug treatment [36]

What began with an obscure lizard and a difficult research question ended by opening one of the most important new chapters in metabolic treatment.

However, increased levels have also been reported (68, 72, 73), raising speculation that elevated plasma DPP-4 activity might constitute a risk factor associated with the deterioration of glycaemic control

Press Release, US FDA, Jun 4, 2021